Phaseline

Targets › SLC5A2

SLC5A2 (Sodium/glucose cotransporter 2): drug programs, companies and trials

32 programs from 32 companies in 258 trials: 86 Phase 4, 78 Phase 2, 52 Phase 3, 42 Phase 1; Metabolic and endocrine, Cardiovascular, Oncology; next expected readout Nov 2026.

Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose at the plasma membrane, with a Na(+) to sugar coupling ratio of 1:1. Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump. (UniProt, P31639)

Open in Phaseline: the race on SLC5A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
Zhujiang HospitalHenagliflozein
SGLT2 inhibitor
SLC5A2Phase 4Type2 Diabetes MellitusNov 2026
Yonsei UniversityEnavogliflozin
SGLT2 inhibitor
SLC5A2Phase 4Nonobstructive Hypertrophic Cardiomyopathy; Atrial Fibrillation; Diabetes Mellitus, Type 2Nov 2026
AstraZenecaDapagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Chronic Kidney Disease; Heart Failure and Impaired Kidney Function; Chronic Kidney Disease and Hypertension; Type 2 Diabetes Mellitus …Dec 2026
Children's Hospital Medical Center, CincinnatiSGLT-2 inhibitor
SGLT-2 inhibitor
SLC5A2Phase 4Diabetes Mellitus, Type 2Dec 2026
JW PharmaceuticalEmpagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Type 2 Diabetes Mellitus (T2DM)Mar 2027
Odense University HospitalDapagliflozin Propanediol
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Kidney Transplantation RecipientsJun 2027
Yale UniversityBexagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Sleep ApneaSep 2027
University of MichiganCanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Type 2 DiabetesDec 2027
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineHenagliflozin
SGLT2 inhibitor
SLC5A2Phase 4Diabetes Mellitus, Type 2Dec 2027
Hangzhou Zhongmei Huadong Pharmaceuticalganagliflozin
SGLT-2 inhibitor
SLC5A2Phase 4T2DM (Type 2 Diabetes Mellitus)Dec 2027
National Heart Centre SingaporeSGLT2 Inhibitor
Sodium glucose cotransporter 2 inhibition
SLC5A2Phase 4Diabetes MellitusJun 2034
Fudan UniversityCanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Type 2 Diabetes Mellitus–
Boryung PharmaceuticalDapagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Type 2 Diabetes; Diabetes Mellitus; Diabete Mellitus–
Getz PharmaErtugliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Liver Fat; Heart Failure; Ketones, Metabolism–
Samsung Medical CenterSGLT2 inhibitor
Sodium-glucose cotransporter 2 inhibitor
SLC5A2Phase 4Acute Myocardial Infarction–
Amsterdam UMC, location VUmcertugliflozine
SGLT2 inhibitor
SLC5A2Phase 4Type 2 Diabetes–
THPharmDapagliflozin (THP-00101)
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 3Type 2 DiabetesDec 2026
Boehringer IngelheimEmpagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 3Chronic Kidney Disease; Heart Failure; Healthy; Diabetes …Dec 2026
Lexicon PharmaceuticalsSotagliflozin
Sodium/glucose cotransporter 1 inhibitor; Sodium/glucose cotransporter 2 inhibitor
SLC5A1, SLC5A2Phase 3Obstructive Cardiomyopathy, Hypertrophic; Diabetic Nephropathies; Cardiovascular Diseases; Type 1 DiabetesJan 2027
Prof. Dr. med. Ingo EitelSGLT2
SGLT2 inhibitor
SLC5A2Phase 3Atrial HypertensionMay 2032
Dong-A STDA5221-T
SGLT-2 inhibitor
SLC5A2Phase 3Type 2 Diabetes–
Ottawa Heart Institute Research CorporationCanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 2Diabetes Type 2Dec 2026
University of Colorado, Denvercanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 2Type 2 DiabetesDec 2026
National Taiwan University Hospitalcanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 2Acute Kidney InjuryJul 2027
Memorial Sloan Kettering Cancer CenterCanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 2Breast CancerOct 2027
McGill University Health Centre/Research Institute of the McGill University Health CentreCanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 2ESRD; ESRD, CKD Stage 4, CKD Stage 5Feb 2028
Minneapolis Heart Institute FoundationSGLT2 inhibitor
Sodium glucose co-transporter 2 inhibitor
SLC5A2Phase 2Heart AttackDec 2028
University of Maryland, BaltimoreCanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 1Diabetes Mellitus, Type 2Dec 2026
Jonsson Comprehensive Cancer CenterAlpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
SGLT2-targeting radioactive glucose tracer for PET imaging
SLC5A2Phase 1Lung AdenocarcinomaOct 2027
University of VirginiaBexagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 1Angina Patients With Non-obstructive Coronary Artery DiseaseOct 2027
West China HospitalCanagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 1Colorectal Cancer; Solid TumorJul 2028

Conditions

Type 2 Diabetes (13) Heart Failure (9) Chronic Kidney Diseases (7) Breast Cancer (6) Diabetes Mellitus, Type 2 (6) Diabetes Mellitus (5) Acute Kidney Injury (4) Type 2 Diabetes Mellitus (T2DM) (4) Obstructive Sleep Apnea (4) Chronic Kidney Disease and Hypertension (3) Type 2 Diabetes Mellitus (3) Obesity (3)

Modalities

small molecule (30), mixed (2)

Companies

THPharm (1) West China Hospital (1) Boryung Pharmaceutical (1) AstraZeneca (1) Lexicon Pharmaceuticals (1) University of Virginia (1) Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1) Prof. Dr. med. Ingo Eitel (1) Jonsson Comprehensive Cancer Center (1) Samsung Medical Center (1) Yonsei University (1) Getz Pharma (1) Boehringer Ingelheim (1) Brigham and Women's Hospital (1) McGill University Health Centre/Research Institute of the McGill University Health Centre (1) University of Michigan (1) University of Maryland, Baltimore (1) Ottawa Heart Institute Research Corporation (1) Dong-A ST (1) Zhujiang Hospital (1)

Related targets

SLC5A1 (1) SLC6A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) OPRM1 (1) NR3C2 (1) AGTR1 (1) IL4R (1) SLC6A4 (1) HTR2A (1) HTR2C (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.